Objective-To identify a plasma biomarker of atheromatous disease. Methods and Results-Surface-enhanced laser desorption ionization-time-of-flight mass spectrometry was used to identify possible plasma protein biomarkers of atheromatous disease in patients presenting with chronic stable angina pectoris by comparing those with 3-vessel disease with those without any evidence of coronary artery disease. The level of a 14.7-kDa protein was elevated; this protein was isolated and identified as a lysozyme. Arterial plasma lysozyme levels, measured by immunoassay, confirmed this observation in separate cohorts of patients. The application of arterial plasma lysozyme levels to 197 patients with varying degrees of coronary artery disease, using a cutoff value of 1.5 g/mL, was able to distinguish patients with 1 or more occluded coronary arteries, with 86% sensitivity and 93% specificity. Of 20 patients with carotid atheroma, 19 had increased arterial plasma levels. In contrast, C-reactive protein levels showed no association with disease severity. Venous lysozyme levels in patients with carotid atheroma were shown to decrease after intensive atorvastatin treatment. Key Words: atherosclerosis Ⅲ coronary artery disease Ⅲ lysozyme Ⅲ plasma Ⅲ SELDI-TOF MS A n estimated 80 million US adults (ie, 1 in 3) have some form of cardiovascular disease (CVD) secondary to atherosclerosis. 1 The early detection and accurate assessment of vascular atheromatous plaques permit timely intervention with lifestyle changes and pharmacological agents. The detection and assessment of atheroma are dependent on functional test results and/or access to imaging. For example, the evaluation of patients with suspected coronary artery disease (CAD) comprises exercise stress testing, followed by coronary angiography. 2 However, meta-analyses have shown that exercise stress testing has a sensitivity of only 65% to 70% and a specificity of only 70% to 75%. 3, 4 Approximately 15% to 20% of patients referred for coronary angiography after exercise stress testing have no sign of atheromatous coronary disease. 5 Other noninvasive methods of diagnosis, such as myocardial perfusion scanning and stress echocardiography, fare better (sensitivity, 75% to 85%; specificity, 85% to 90%). 6 Coronary angiography using multidetector row computed tomography appears to have the best diagnostic accuracy (sensitivity, 85% to 90%; specificity, 85% to 95%) 7, 8 ; however, these findings vary with patient and lesion characteristics. 7 Carotid atheroma can be detected by Doppler ultrasonography; more sophisticated techniques, still under investigation, are required to assess plaque vulnerability. A soluble biomarker of vascular atheroma would have considerable clinical utility.
A n estimated 80 million US adults (ie, 1 in 3) have some form of cardiovascular disease (CVD) secondary to atherosclerosis. 1 The early detection and accurate assessment of vascular atheromatous plaques permit timely intervention with lifestyle changes and pharmacological agents. The detection and assessment of atheroma are dependent on functional test results and/or access to imaging. For example, the evaluation of patients with suspected coronary artery disease (CAD) comprises exercise stress testing, followed by coronary angiography. 2 However, meta-analyses have shown that exercise stress testing has a sensitivity of only 65% to 70% and a specificity of only 70% to 75%. 3, 4 Approximately 15% to 20% of patients referred for coronary angiography after exercise stress testing have no sign of atheromatous coronary disease. 5 Other noninvasive methods of diagnosis, such as myocardial perfusion scanning and stress echocardiography, fare better (sensitivity, 75% to 85%; specificity, 85% to 90%). 6 Coronary angiography using multidetector row computed tomography appears to have the best diagnostic accuracy (sensitivity, 85% to 90%; specificity, 85% to 95%) 7, 8 ; however, these findings vary with patient and lesion characteristics. 7 Carotid atheroma can be detected by Doppler ultrasonography; more sophisticated techniques, still under investigation, are required to assess plaque vulnerability. A soluble biomarker of vascular atheroma would have considerable clinical utility.
We have used surface-enhanced laser desorption ionization-time-of-flight (SELDI-TOF) mass spectrometry (MS) to conduct an unbiased examination of arterial blood from patients with symptomatic CAD to identify discriminating protein biomarkers of atheroma. We detected circulating lysozyme, and then used a specific immunoassay to explore the relationship between circulating levels and the severity of coronary atheroma compared with C-reactive protein (CRP) levels. We also examined (1) the relationship between circulating levels and macrophage activity in carotid plaques and (2) the response to atorvastatin therapy.
were recruited for this study. An initial biomarker discovery phase comprised age-and sex-matched patients attending the Cardiac Catheter Laboratory at Wycombe Hospital, High Wycombe, UK with either no evidence of coronary atheroma (normal vessels [NV]; nϭ20) or 3-vessel disease (3VD; nϭ20) (cohort 1). These findings were evaluated in a separate cohort of patients with NV (nϭ39) and 3VD (nϭ28) who attended the Cardiac Catheter Laboratory at Hammersmith Hospital, London, UK (cohort 2). Subsequently, an unselected group of patients (nϭ197) was recruited from those attending the Cardiac Catheter Laboratory at Wycombe Hospital to determine the application of the test in those with a range of disease severity (cohort 3). The severity of atherosclerosis was based on published guidelines. 9 In each case, arterial blood was collected from a femoral or radial artery through the catheter used in the angiography procedure before the administration of any drugs or other reagents and just before the procedure began. In some cases, venous blood was collected from the median cubital vein. Arterial blood from patients with carotid atheroma undergoing carotid endarterectomy at Charing Cross Hospital, London, UK (cohort 4) was collected preoperatively from the radial artery of the arm contralateral to the operated on carotid artery. All patients recruited in this study were hemodynamically stable, with no evidence of myocardial infarction, unstable angina, or heart failure in the preceding 12 months. Local ethics approvals were obtained before sample collection; all patients gave informed consent.
In addition, venous plasma samples from patients with carotid atheroma who underwent intervention treatment (cohort 5) were obtained subsequent to the completion of a separate study (Atorvastatin Therapy: Effects on Reduction Of Macrophage Activity Study [ATHEROMA] 10 ).
Protein Profiling, Identification, Measurement and Immunohistochemistry
Analysis of plasma samples by SELDI-TOF MS and purification of the candidate biomarker are described in detail in the Supplemental Material (available online at http://atvb.ahajournals.org).
Enzyme immunoassay (EIA) kits were used to measure lysozyme (Biomedical Technologies, Stoughton, Mass) and CRP (R&D Systems Europe Ltd, Abingdon, UK). Interassay variations were 7.0% and 6.5%, respectively. An assay kit (EnzChek Lysozyme Assay Kit; Invitrogen Ltd, Paisley, UK) was used to determine lysozyme activity. Coronary artery atherosclerotic plaques were formaldehyde fixed, paraffin embedded, sectioned, and immunostained with rabbit antilysozyme (Dako UK Ltd, Ely, UK).
Statistical Analyses
Values are expressed as meanϮSEM, where appropriate. Categorical data analyses were performed using Spearman regression analysis and t test, 1-way ANOVA, or the 2 test. Multiple regression modeling was performed for adjustment of potential confounding factors. Sensitivity and specificity testing was calculated using receiver operating characteristic (ROC) curves. Statistical analyses were performed using computer software (STATISTICA 6.1; Statsoft Inc, Tulsa, Mass; or GraphPad Prism 4.0; GraphPad Software, San Diego, Calif).
Results

Biomarker Discovery
Arterial plasma samples from cohort 1, comprising patients with 3VD and NV and matched for age and sex, were analyzed using SELDI-TOF MS ( Figure 1A) . Analysis of the data indicated that 1 protein ion in particular (mass [m]/ charge [z] 14735) was able to differentiate clearly between the patient groups, with an overall 3-fold higher intensity in the 3VD group compared with the NV group (PϽ0.001) ( Figure 1B and C) . The protein was subsequently purified and identified as lysozyme (details are provided in the Supplemental Material). The levels of lysozyme in cohort 1 were then measured by EIA, which confirmed the increase in the 3VD group ( Figure 1D ). In fact, EIA measurements indicated better differentiation between the patient groups than was evident by SELDI-TOF MS, which reflects the use of a more specific assay.
Discriminatory Power of Arterial Plasma Lysozyme
The performance of lysozyme to differentiate patients with NV from patients with 3VD was tested on a separate group (cohort 2), which was not selected for age or sex. Plasma lysozyme levels remained elevated in patients with 3VD (7.11Ϯ0.62 g/mL, nϭ28) compared with patients with NV (2.10Ϯ0.19 g/mL, nϭ39) (PϽ0.001) ( Figure 2 ). ROC curve analysis produced an area under the curve of 0.98 at a cutoff of 3.0 g/mL; 82% sensitivity and 100% specificity were achieved (Table 1) . Arterial plasma lysozyme levels were then measured in a blinded manner in samples taken from patients in cohort 3, which represented an unselected cross section of patients presenting for angiography. The findings at angiography were used as a surrogate measure of the severity of atherosclerosis. Patients with NV had a lysozyme level of 1.14Ϯ0.07 g/mL (nϭ42), which was not significantly different from the levels in those with minimal VD (1.21Ϯ0.07 g/mL, nϭ35) (Pϭ0.34). The level was increased 2-fold in those with 1VD (2.15Ϯ0.17 g/mL, nϭ38) (PϽ0.001), 3-fold in those with 2VD (3.46Ϯ0.30 g/mL, nϭ36) (PϽ0.001), and 11-fold in those with 3VD (11.29Ϯ0.46 g/mL, nϭ46) (PϽ0.001) ( Figure 2A ).
The application of a cutoff of 3.0 g/mL, determined from ROC analysis of data from cohort 2 to data from cohort 3, resulted in complete discrimination between patients with 3VD and patients with NV (100% sensitivity and specificity, PϽ0.001) ( Table 1) . Furthermore, 19 of 20 patients with carotid atherosclerosis (cohort 4) had lysozyme levels of greater than 3.0 g/mL. ROC analysis was then performed on all of the data from cohort 3 to test the discriminatory power of lysozyme in segregating patients with intermediate disease severity (Table 1) . A cutoff of 1.5 g/mL was appropriate to separate patients with NV from those with 1VD, and incremental increases successfully classified patients with CAD with increasing VD (Table 1 and Table 2 ). Because there was no difference in levels between patients with NV and those with minimal VD, a likely practical application of plasma lysozyme in patient diagnosis may be in the setting of chronic stable angina; patients with either normal or minimally affected coronary arteries can be distinguished from those with a degree of coronary disease that requires treatment. To examine this, data from the NV and minimal VD groups were combined and compared with a combination of the other VD groups; this gave sensitivity and specificity values of 86% and 93%, respectively, using a cutoff of 1.5 g/mL (Table 1) .
There was some variation in the composition of the patient groups, which required further consideration. Patient grouping according to plasma lysozyme levels showed age, sex, creatinine level, and treatment with drugs (angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, and ␤-blockers) as potential confounders (Table 2 ). Adjustment by multivariate regression modeling was used to account for these potential confounders. In each case, the association between lysozyme levels and coronary VD, evident from the raw data, remained significant after adjustment (PϽ0.001). There was also no meaningful correlation (rϽ0.5) between lysozyme levels and other patient clinical parameters (Table 2) . Thus, lysozyme appears to be an independent marker of coronary disease status. In support of this, classification based on traditional risk factors alone was improved with the addition of lysozyme data. However, this combined model performed similarly to a model using just lysozyme without consideration of the risk factors (Table 1) . CRP levels were not significantly different between the NV and the other VD groups in any of the cohorts ( Figure  2B ). ROC analyses indicated that CRP levels were much worse at classifying the patient groups in all cases ( Table 1) .
Estimation of Arterial Plasma Lysozyme Activity
It is also possible to estimate plasma lysozyme levels by measuring enzyme activity. The arterial plasma lysozyme activity was increased 2-fold (PϽ0.001) in patients with 3VD (30.8Ϯ2.2 U/mL, nϭ25) versus patients with NV (13.5Ϯ1.1 U/mL, nϭ12). However, lysozyme activity correlated poorly with plasma levels, as determined by EIA (rϽ0.1). In terms of specific activity (ie, the activity to quantity ratio), lysozyme was clearly more active in the NV group (13.4Ϯ2.0 U/g) compared with the 3VD group (3.0Ϯ0.4 U/g) (PϽ0.001). This indicates that most of the lysozyme detected in the plasma of patients with 3VD by EIA was partially or completely inactive.
Effect of Treatment With Atorvastatin
Lysozyme levels were measured in venous plasma samples collected from patients with carotid atherosclerosis taking part in the ATHEROMA study. Those in the pretreatment group (nϭ34) had a level of 1.56Ϯ0.13 g/mL, which was elevated compared with nonatherosclerotic donors (1.08Ϯ0.13 g/mL, nϭ16) (Pϭ0.02) and not significantly different compared with patients with 3VD (from cohort 2) (2.15Ϯ0.40 g/mL, nϭ17) (PϾ0.05). Lysozyme levels were significantly reduced in patients after treatment with highdose atorvastatin (80 mg/d, nϭ21, Pϭ0.02), but were unchanged in those receiving the lower dose (10 mg/d, nϭ13) Figure 2 . Arterial plasma lysozyme and CRP levels in patients undergoing diagnostic coronary angiography and carotid endarterectomy. Box-and-whisker plots indicate median, interquartile distribution, and range of arterial plasma lysozyme (A) and CRP (B) levels. Statistically significance differences in lysozyme levels vs the NV group from either cohort 2 or cohort 3 are indicated as ### and ***, respectively (PϽ0.001, t test). The corresponding CRP levels were not significantly different (PϾ0.05). In each comparative data set, the cutoff value that gave the highest predictive values of sensitivity and specificity is shown. For CRP level, in most cases, the cut off value was 3.0 g/mL; when it was not, the performance at this value is reported in parentheses. Statistical differences between groups were determined using the t test.
†For lysozyme and CRP levels, the cutoff values are given in micrograms per milliliter.
( Figure 3 ). In addition, levels were significantly lower in the high-dose compared with the low-dose atorvastatin group (Pϭ0.008). These results are consistent with the assessment of plaque macrophage activity and number, as determined by MRI measurement of ultrasmall superparamagnetic iron oxide uptake. In patients taking high-dose atorvastatin, changes in ultrasmall superparamagnetic iron oxide uptake correlated with changes in plasma lysozyme levels (rϭ0.61, PϽ0.01). However, lysozyme level did not correlate with the inflammatory markers myeloperoxidase (rϭ0.10), CRP (rϭ0.14), or lipoprotein-associated phospholipase A2 (rϭ0.34).
Lysozyme in Atherosclerotic Plaques
Immunostaining for lysozyme in coronary artery atherosclerotic plaques showed intense staining in foam cells and in recently migrated macrophages. Staining was also evident in the lipid necrotic core and in endothelial cells, but not in the fibrous cap (Supplemental Figure II) .
Discussion
This study identified lysozyme in arterial plasma from patients with symptomatic coronary atheroma, verified by coronary angiography, as a potential accessible biomarker of atheromatous disease. Increased levels were found to correlate closely with disease severity, indicating its potential as a diagnostic tool to aid in the assessment of such patients. In contrast, CRP levels showed no association with disease severity. Lysozyme levels were also elevated in patients with carotid atheroma, indicating relevance to atheromatous disease in other vascular beds. At a cutoff of 1.5 g/mL, lysozyme was able to distinguish patients with 1 or more occluded coronary arteries with 86% sensitivity and 93% specificity. If confirmed in larger prospective studies, this would compare favorably with other putative biomarkers of atherosclerosis. Elevated plasma or serum levels of phospholipase A2, 11 CRP, 12 CD40 ligand, 13 myeloperoxidase, 13 lipocalin-type prostaglandin D, 14 glycated albumin, 15 F11 receptor/junctional adhesion molecule, 16 osteoprotegerin, 17 and various chemokines and cytokines 18 have been reported; some of these appear to associate closely with the risk of future events. However, where stated, diagnostic performance values of sensitivity and specificity were relatively poor, as were the results of area under the curve ROC analyses. Certainly, in this current study, CRP levels proved to be of little diagnostic value; CRP appears to be discriminatory in only large patient cohorts. 14 The diag- nostic accuracy of arterial lysozyme is similar to the most accurate noninvasive diagnostic test available, multidetector row spiral computed tomography, which has a sensitivity of 85% to 90% and a specificity of 85% to 95%. 8 Notably, arterial plasma lysozyme levels were particularly useful for the identification of patients with 3VD. Because the levels of plasma lysozyme appear to be related to the degree of severity of CAD, such information may aid the prioritization of patients for further clinical investigation. Arterial plasma from patients with CAD comprises a high level of predominantly inactive lysozyme. Unlike circulating monocytes that contain active lysozyme, lysozyme in human atherosclerotic plaques is inactive. 19 The reason for this is explained by the colocalization of myeloperoxidase and lysozyme in foam cells. 20, 21 Myeloperoxidase catalyzes the formation of hypochlorous acid, which has been shown to react with lysozyme, causing its inactivation. 21 Thus, lysozyme released from atheromatous plaques into arterial blood is likely to be in an inactive form. The correlation between arterial plasma lysozyme with the severity of CAD and the decrease in macrophage density after high-dose atorvastatin treatment, coupled with localization of lysozyme in plaque macrophages and foam cells, is consistent with the hypothesis that plaque is the source of increased plasma lysozyme levels in patients with CVD. Therefore, it is plausible to suggest that plasma lysozyme may be used as a biomarker of atheromatous disease.
In terms of clinical utility, venous blood is more readily and routinely sampled than arterial blood. Venous plasma lysozyme levels were elevated in patients with CAD and carotid artery disease, but less so than arterial plasma levels. The difference between venous and arterial levels may be explained by the rapid clearance of the inactive form of lysozyme. Elevated venous plasma lysozyme levels in those with carotid artery disease were attenuated after treatment with high-dose atorvastatin and are consistent with the observed decrease in plaque macrophage activity. The number of samples available for lysozyme measurement from cohort 5 was limited; nevertheless, the results justify further studies with a larger cohort to ascertain the usefulness of venous lysozyme as an indictor of CVD.
Further future studies should determine the biological variation of plasma lysozyme in individuals, assess the performance in an unselected population, and address the relationship of lysozyme levels to different stages of atheroma, including examination of the effect of plaque stability. Factors that may confound the interpretation of elevated lysozyme levels also need to be considered. The activity of venous serum lysozyme is elevated in some cases of granulamatous diseases, such as sarcoidosis, 22 active inflammatory bowel disease, 23 active tuberculosis, 24 leprosy, 24 and myeloid leukemia 25 ; however, these conditions are usually apparent from clinical assessment and investigations. Lysozyme is mostly (75%) catabolized by the kidneys. 26 Levels of lysozyme activity did not correlate with its renal clearance in patients with myeloid leukemia. 25 Similarly, there was no correlation between lysozyme levels or activity and creatinine levels among the patients with CAD. However, we cannot exclude the possibility that severe renal insufficiency may be a confounding factor in patients with CVD. Also, the levels in patients with other inflammatory conditions, such as arthritis, should be investigated. In those with diabetes, there is an increase in advanced glycation end products; it has been suggested that lysozyme aids their clearance. 27 Such an interaction could affect lysozyme levels, although the lack of correlation of lysozyme with diabetes was not supportive (Table 2 ). Increased levels of lysozyme have been reported in the saliva as a consequence of oral infection; this has been associated with a risk of developing coronary heart disease. 28 However, salivary levels appear to be only locally produced and unrelated to blood levels. 28 In conclusion, circulating lysozyme levels are elevated in patients with CAD and carotid atheroma and are related to the severity of atheromatous disease. We suggest that measurement of plasma levels rather than activity may be useful in the detection of CVD. This suggestion is based on (1) biological plausibility, (2) the correlation between circulating levels with macrophage activity in the plaque and the severity of disease, and (3) the observation that levels decrease with intensive atorvastatin treatment. The measurement of lysozyme levels in a larger clinical trial of CVD would be helpful in validating our observations and investigating the clinical utility of measurements as a predictor of cardiovascular events.
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